ReviewFrontiers in immunology2026
Advances in research on the mechanisms of anti-inflammation of silybin: a review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silybin, as the main active component of milk thistle, has attracted significant attention in recent medical research due to its remarkable anti-inflammatory effect. Inflammatory responses are an important mechanism in the pathogenesis of various clinical diseases, and controlling inflammation is crucial for the prevention and treatment of diseases. Existing studies have shown that silybin can regulate the release of inflammation-related cell factors, inhibit oxidative stress responses, modulate apoptosis, and immune function, thereby exerting multi-target and multi-pathway anti-inflammatory effects. This article systematically reviews the anti-inflammatory mechanisms of silybin in various clinical diseases, including neurological diseases, respiratory diseases, and digestive system diseases, and analyzes the latest progress in its mechanisms of action, aiming to provide a theoretical basis for its clinical applications and promote the development and application of silybin as a novel anti-inflammatory drug.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.